306 related articles for article (PubMed ID: 36551260)
1. The Potential Roles of Post-Translational Modifications of PPARγ in Treating Diabetes.
Ji X; Zhang W; Yin L; Shi Z; Luan J; Chen L; Liu L
Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551260
[TBL] [Abstract][Full Text] [Related]
2. Controlling a master switch of adipocyte development and insulin sensitivity: covalent modifications of PPARγ.
Floyd ZE; Stephens JM
Biochim Biophys Acta; 2012 Jul; 1822(7):1090-5. PubMed ID: 22504298
[TBL] [Abstract][Full Text] [Related]
3. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
4. PPARγ signaling and metabolism: the good, the bad and the future.
Ahmadian M; Suh JM; Hah N; Liddle C; Atkins AR; Downes M; Evans RM
Nat Med; 2013 May; 19(5):557-66. PubMed ID: 23652116
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress.
Cho N; Momose Y
Curr Top Med Chem; 2008; 8(17):1483-507. PubMed ID: 19075761
[TBL] [Abstract][Full Text] [Related]
6. Pleiotropic effects of PPARγ agonist on hemostatic activation in type 2 diabetes mellitus.
Ferroni P; Della-Morte D; Pileggi A; Riondino S; Rundek T; Ricordi C; Guadagni F
Curr Vasc Pharmacol; 2013 May; 11(3):338-51. PubMed ID: 23650948
[TBL] [Abstract][Full Text] [Related]
7. PPARγ signaling and emerging opportunities for improved therapeutics.
Wang S; Dougherty EJ; Danner RL
Pharmacol Res; 2016 Sep; 111():76-85. PubMed ID: 27268145
[TBL] [Abstract][Full Text] [Related]
8. Revisiting PPARγ as a target for the treatment of metabolic disorders.
Choi SS; Park J; Choi JH
BMB Rep; 2014 Nov; 47(11):599-608. PubMed ID: 25154720
[TBL] [Abstract][Full Text] [Related]
9. Advances on PPARγ Research in the Emerging Era of Precision Medicine.
Lu P; Zhao Z
Curr Drug Targets; 2018; 19(6):663-673. PubMed ID: 28641522
[TBL] [Abstract][Full Text] [Related]
10. Insulin resistance and PPAR insulin sensitizers.
Bhatia V; Viswanathan P
Curr Opin Investig Drugs; 2006 Oct; 7(10):891-7. PubMed ID: 17086933
[TBL] [Abstract][Full Text] [Related]
11. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
Derosa G; Maffioli P
Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
[TBL] [Abstract][Full Text] [Related]
12. [Recent trends in PPARgamma agonist development of thiazolidinediones and non-thiazolidinediones].
Tanaka T
Nihon Rinsho; 2010 Feb; 68(2):249-55. PubMed ID: 20158092
[TBL] [Abstract][Full Text] [Related]
13. Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes.
Soccio RE; Chen ER; Lazar MA
Cell Metab; 2014 Oct; 20(4):573-91. PubMed ID: 25242225
[TBL] [Abstract][Full Text] [Related]
14. Covalent peroxisome proliferator-activated receptor gamma adduction by nitro-fatty acids: selective ligand activity and anti-diabetic signaling actions.
Schopfer FJ; Cole MP; Groeger AL; Chen CS; Khoo NK; Woodcock SR; Golin-Bisello F; Motanya UN; Li Y; Zhang J; Garcia-Barrio MT; Rudolph TK; Rudolph V; Bonacci G; Baker PR; Xu HE; Batthyany CI; Chen YE; Hallis TM; Freeman BA
J Biol Chem; 2010 Apr; 285(16):12321-33. PubMed ID: 20097754
[TBL] [Abstract][Full Text] [Related]
15. A novel peroxisome proliferator-activated receptor gamma ligand improves insulin sensitivity and promotes browning of white adipose tissue in obese mice.
Wu D; Eeda V; Undi RB; Mann S; Stout M; Lim HY; Wang W
Mol Metab; 2021 Dec; 54():101363. PubMed ID: 34710641
[TBL] [Abstract][Full Text] [Related]
16. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of novel thiazolidinediones as PPARγ/FFAR1 dual agonists.
Darwish KM; Salama I; Mostafa S; Gomaa MS; Helal MA
Eur J Med Chem; 2016 Feb; 109():157-72. PubMed ID: 26774923
[TBL] [Abstract][Full Text] [Related]
18. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor gamma binding properties.
Li Y; Wang Z; Furukawa N; Escaron P; Weiszmann J; Lee G; Lindstrom M; Liu J; Liu X; Xu H; Plotnikova O; Prasad V; Walker N; Learned RM; Chen JL
J Biol Chem; 2008 Apr; 283(14):9168-76. PubMed ID: 18263587
[TBL] [Abstract][Full Text] [Related]
19. Molecular basis of selective PPARgamma modulation for the treatment of Type 2 diabetes.
Gelman L; Feige JN; Desvergne B
Biochim Biophys Acta; 2007 Aug; 1771(8):1094-107. PubMed ID: 17459763
[TBL] [Abstract][Full Text] [Related]
20. Targeting peroxisome proliferator-activated receptor gamma for generation of antidiabetic drug.
Karak M; Bal NC; Bal C; Sharon A
Curr Diabetes Rev; 2013 Jul; 9(4):275-85. PubMed ID: 23746081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
